Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Share-based Compensation (2020 - 2023)

Historic Share-based Compensation for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to $3.3 million.

  • Terns Pharmaceuticals' Share-based Compensation rose 2214.37% to $3.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $25.5 million, marking a year-over-year increase of 13714.71%. This contributed to the annual value of $15.6 million for FY2024, which is 3880.4% down from last year.
  • Terns Pharmaceuticals' Share-based Compensation amounted to $3.3 million in Q4 2023, which was up 2214.37% from $14.1 million recorded in Q3 2023.
  • Terns Pharmaceuticals' Share-based Compensation's 5-year high stood at $14.1 million during Q3 2023, with a 5-year trough of $190000.0 in Q2 2020.
  • For the 4-year period, Terns Pharmaceuticals' Share-based Compensation averaged around $2.9 million, with its median value being $2.6 million (2021).
  • As far as peak fluctuations go, Terns Pharmaceuticals' Share-based Compensation surged by 90473.68% in 2021, and later surged by 537.25% in 2022.
  • Terns Pharmaceuticals' Share-based Compensation (Quarter) stood at $786000.0 in 2020, then soared by 224.43% to $2.6 million in 2021, then grew by 5.37% to $2.7 million in 2022, then increased by 22.14% to $3.3 million in 2023.
  • Its Share-based Compensation stands at $3.3 million for Q4 2023, versus $14.1 million for Q3 2023 and $4.2 million for Q2 2023.